Doctors have access to a range of evidence-based early interventions after diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD). Early diagnosis also provides the opportunity to prepare financial and end-of-life plans while cognitive impairment remains mild.2,3
The current pharmacological landscape for managing patients with Alzheimer’s disease includes symptomatic treatments and treatments for comorbidities such as depression.4
Discover how biomarker confirmation may lead to effective intervention.
Get tips for discussing MCI due to AD diagnosis and biomarker testing options with your patients.
As of 2017, 48% of caregivers were unpaid while caring for a spouse, parent, or family member. Dementia caregivers tend to provide more extensive assistance as the disease progresses, with an emphasis on self-care and mobility. The care required of family members can result in increased emotional stress and feelings of depression. Tailored interventions can have a positive impact on the well-being of caregivers.
Continued support for caregivers is instrumental in treating Alzheimer’s disease holistically.